CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,976,580
- in 4 filings, $5.0M under 10b5-1 plans
Net −$4,976,580. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-02-25 | Hunt Anthony Chief Executive Officer | Sale | −1,699 | $92.34 | $157K | 229,449 |
| 2020-02-25 | Hunt Anthony Chief Executive Officer | Sale | −8,412 | $91.66 | $771K | 221,037 |
| 2020-02-25 | Hunt Anthony Chief Executive Officer | Sale | −1,624 | $90.22 | $147K | 219,413 |
| 2020-02-25 | Hunt Anthony Chief Executive Officer | Exercise or conversion | +10,210 | $16.55 | $169K | 229,623 |
| 2020-02-25 | Hunt Anthony Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −11,735 | 53,240 | ||
| 2020-02-25 | Hunt Anthony Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −10,210 | 7,917 | ||
| 2020-02-24 | Cox John Director | Sale | −100 | $94.85 | $9K | 7,136 |
| 2020-02-24 | Cox John Director | Sale | −4,355 | $92.76 | $404K | 2,781 |
| 2020-02-21 | DAWES KAREN A Director | Sale | −300 | $101.06 | $30K | 116,734 |
| 2020-02-21 | DAWES KAREN A Director | Sale | −945 | $99.85 | $94K | 115,789 |
| 2020-02-21 | DAWES KAREN A Director | Sale | −906 | $99.12 | $90K | 114,883 |
| 2020-02-21 | DAWES KAREN A Director | Sale | −1,849 | $97.52 | $180K | 113,034 |
| 2019-12-16 | KURIYEL RALF Senior VP, R&D | Shares withheld for taxes | −295 | $90.43 | $27K | 26,508 |
| 2019-12-05 | Snodgres Jon Chief Financial Officer | Exercise or conversion | +2,000 | $24.50 | $49K | 30,239 |
| 2019-12-05 | Snodgres Jon Chief Financial Officer | Exercise or conversion | +1,957 | $26.05 | $51K | 32,196 |
| 2019-12-05 | Snodgres Jon Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) | −2,000 | 0 | ||
| 2019-12-05 | Snodgres Jon Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) | −1,957 | 3,170 | ||
| 2019-09-19 | Hunt Anthony Chief Executive Officer | Exercise or conversion | +20,000 | $16.55 | $331K | 223,013 |
| 2019-09-19 | Hunt Anthony Chief Executive Officer | Sale | −638 | $81.82 | $52K | 222,375 |
| 2019-09-19 | Hunt Anthony Chief Executive Officer | Sale | −2,510 | $83.01 | $208K | 219,865 |
Page 40 of 42 · 832 trades